Aisling Capital Management LP — 13F holdings

Aisling Capital Management LP reported 14 holdings worth $472M in its 13F filing for Q2 2026, filed August 13, 2026.

Largest positions

1. BBIO BRIDGEBIO PHARMA INC — $342M (72.5%)
2. GLUE MONTE ROSA THERAPEUTICS INC — $37.6M (8.0%)
3. SNDX Syndax Pharmaceuticals Inc — $28.8M (6.1%)
4. CMPS COMPASS PATHWAYS PLC — $20.3M (4.3%)
5. BCAX BICARA THERAPEUTICS INC — $16.9M (3.6%)
6. BBOT BRIDGEBIO ONCOLOGY THERAPEUT — $7.76M (1.6%)
7. SRRK SCHOLAR ROCK HLDG CORP — $4.24M (0.9%)
8. URGN UROGEN PHARMA LTD — $3.97M (0.8%)
9. BMEA BIOMEA FUSION INC — $3.01M (0.6%)
10. ACRS ACLARIS THERAPEUTICS INC — $2.30M (0.5%)